AX-2026-042875

TB-500 · 10 mg declared · Nantong Guangyuan Chemical Co., Ltd. · lot GGPE-2601-B2671

PASSVERIFIED

Report ID: AX-2026-042875
Compound: TB-500
Compound class: Tissue-repair and immunomodulatory peptides
Supplier: GGPeps — Nantong Guangyuan Chemical Co., Ltd.
Batch / lot: GGPE-2601-B2671
Declared label claim: 10mg
Laboratory: Nordanalyt Laboratories
Assay date: 31 May 2026
Submitted: 18 Jun 2026
Quarter: 2026-Q2
Submitter: r.kjaer
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the tissue-repair and immunomodulatory peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 35 min gradient, 214 nm	99.57	% area	≥ 98.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.43	% area	≤ 1.5	PASS
Largest single impurity	RP-HPLC — C-terminal amide (−1 Da)	0.29	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	887.4964	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	887.4976	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+1.3	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	4.05	%	≤ 10.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	6.03	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.84	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.38	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.61	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 35 min gradient	9.14	min	9.07 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.95	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	58,195	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Thr]-diastereomer	0.83	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 35 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 58,195, and skew follows the reported asymmetry factor of 0.95. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.29 % impurity against a 99.57 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	TB-500 — main peak	9.14	4,839,411	99.57	—
2	C-terminal amide (−1 Da)	9.35	14,095	0.29	-0.984
3	[D-Thr]-diastereomer	9.01	4,374	0.09	0.000
4	des-Gln truncate (−128 Da)	8.86	1,458	0.03	-128.059
5	des-acetyl TB-500 (−42 Da)	8.53	972	0.02	-42.011
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 887.4964 Da, computed from C39H69N9O14. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 887.4976 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	444.7555	444.7561	0.0006	53.9
1+	888.5037	888.5049	0.0012	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.60	99.57	divergence +0.01 pp vs batch median
Total impurities (% area)	0.40	0.43
Largest single impurity (% area)	not stated	0.29
Water (%)	2.8	4.05
Counter-ion (%)	not stated	6.03
Peptide content (%w/w)	98.0	not determined
Endotoxin (EU/mg)	not stated	0.38
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 6 d) → laboratory (courier, cold pack, 4 d) → assay.
Assay date: 31 May 2026
Submitted to the index: 18 Jun 2026
Laboratory: Nordanalyt Laboratories, Uppsala, Sweden
Method basis: 35 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 2

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

units_pedant18 Jun 2026

Reported as signed ppm, which is the right convention: direction carries information about calibration that a modulus discards.

lambda_21418 Jun 2026

Detection wavelength does not affect a mass determination but it does affect the purity figure sitting next to it. Both are stated on this record, which is the point.

Section 7

Related records

Same batch — lot GGPE-2601-B2671 n=13

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042870	GGPE-2601-B2671	Janoshik	2026-Q2	99.21	4.45	88.9	Buyer-sourced	1	MARGINAL
AX-2026-042871	GGPE-2601-B2671	PeptideMeter	2026-Q2	99.93	4.85	89.7	Supplier-supplied	1	MARGINAL
AX-2026-042872	GGPE-2601-B2671	Medutest	2026-Q2	99.80	5.26	92.5	Buyer-sourced	0	PASS
AX-2026-042873	GGPE-2601-B2671	Janoshik	2026-Q2	99.30	4.92	103.1	Buyer-sourced	0	PASS
AX-2026-042874	GGPE-2601-B2671	Janoshik	2026-Q2	99.59	4.96	104.3	Buyer-sourced	0	PASS
AX-2026-042876	GGPE-2601-B2671	PeptideMeter	2026-Q2	99.43	4.24	—	Buyer-sourced	0	PASS
AX-2026-042877	GGPE-2601-B2671	Janoshik	2026-Q2	99.67	5.07	105.8	Buyer-sourced	0	PASS
AX-2026-042878	GGPE-2601-B2671	Janoshik	2026-Q2	99.77	4.87	—	Buyer-sourced	1	FAIL
AX-2026-042879	GGPE-2601-B2671	Medutest	2026-Q2	99.93	4.42	98.8	Supplier-supplied	0	PASS
AX-2026-042880	GGPE-2601-B2671	Janoshik	2026-Q2	99.25	4.89	—	Buyer-sourced	0	PASS
AX-2026-042881	GGPE-2601-B2671	Janoshik	2026-Q2	99.69	4.50	—	Buyer-sourced	0	PASS
AX-2026-042882	GGPE-2601-B2671	VendorInvestigate	2026-Q2	99.50	5.12	—	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent TB-500 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041776	ASY	ASY-{CAT}-2167	Janoshik	2026-Q3	99.92	4.61	98.2	Buyer-sourced	0	PASS
AX-2026-041777	ASY	ASY-{CAT}-2167	PeptideMeter	2026-Q3	99.78	4.09	92.8	Buyer-sourced	0	PASS
AX-2026-041782	ASY	ASY-{CAT}-2167	Nordanalyt	2026-Q3	99.93	3.94	—	Buyer-sourced	0	PASS
AX-2026-041774	ASY	ASY-{CAT}-2167	PeptideMeter	2026-Q3	99.93	4.41	96.2	Buyer-sourced	0	PASS
AX-2026-042127	JEEP	JEEP-2602-V8614	Medutest	2026-Q3	99.68	3.55	—	Buyer-sourced	1	FAIL
AX-2026-042021	AMB	AMB-2602-P5987	VendorInvestigate	2026-Q3	99.86	4.79	101.4	Buyer-sourced	0	PASS
AX-2026-041780	ASY	ASY-{CAT}-2167	Janoshik	2026-Q3	99.93	3.48	102.5	Buyer-sourced	1	FAIL
AX-2026-041779	ASY	ASY-{CAT}-2167	Janoshik	2026-Q3	99.84	3.85	—	Buyer-sourced	1	FAIL

Other recent GGPeps records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042784	CJC-1295 (no DAC)	GGPE-2606-E1234	Medutest	2026-Q3	98.27	4.55	—	Buyer-sourced	PASS
AX-2026-042786	CJC-1295 (no DAC)	GGPE-2606-E1234	Janoshik	2026-Q3	98.22	3.77	—	Buyer-sourced	PASS
AX-2026-042858	Selank	GGPE-2603-J2447	VendorInvestigate	2026-Q3	98.87	8.85	99.4	Buyer-sourced	FAIL
AX-2026-042783	CJC-1295 (no DAC)	GGPE-2606-E1234	Janoshik	2026-Q3	98.22	4.45	90.6	Buyer-sourced	PASS
AX-2026-042757	Melanotan II	GGPE-2603-P1474	Janoshik	2026-Q3	99.54	6.78	92.0	Buyer-sourced	PASS
AX-2026-042785	CJC-1295 (no DAC)	GGPE-2606-E1234	PeptideMeter	2026-Q3	97.70	4.64	91.4	Buyer-sourced	FAIL
AX-2026-042756	Melanotan II	GGPE-2603-P1474	Nordanalyt	2026-Q3	99.17	7.04	—	Buyer-sourced	PASS
AX-2026-042755	Melanotan II	GGPE-2603-P1474	Nordanalyt	2026-Q3	99.25	6.58	90.4	Buyer-sourced	PASS